Browse

Use of Hormonal Protection for Chemotherapy-induced Gonadotoxicity

Cited 54 time in Web of Science Cited 56 time in Scopus
Authors
Kim, S. Samuel; Lee, Jung Ryeol; Jee, Byung Chul; Suh, Chang Suk; Ting, Alison; Petroff, Brian; Kim, Seok Hyun
Issue Date
2010-12
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Citation
CLINICAL OBSTETRICS AND GYNECOLOGY; Vol.53 4; 740-752
Keywords
fertility preservationGnRH agonisttamoxifenchemotherapycancergonadotoxicity
Abstract
It is still controversial that GnRH agonist (GnRHa) protects ovarian function from chemotherapy-induced gonadotoxicity. Indeed, the results of many studies related to this issue are neither consistent nor convincing because of the weak study design and the inadequate sample size. We identified 11 prospective controlled studies (8 nonrandomized and 3 randomized) for the systemic review and meta-analysis. The meta-analysis showed that GnRHa cotreatment during chemotherapy can protect ovarian function. However, it is worthy to note that the result of this meta-analysis is influenced by nonrandomized studies. The protective effect of GnRHa will remain elusive until the currently ongoing large, prospective, randomized studies are completed. In addition, tamoxifen, a selective estrogen receptor modulator, may have the protective effect against loss of follicles and ovarian function, which was caused by chemotherapy.
ISSN
0009-9201
Language
English
URI
http://hdl.handle.net/10371/76789
DOI
https://doi.org/10.1097/GRF.0b013e3181f96cb1
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse